

Karin Neukam

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9036290/karin-neukam-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79
papers

1,369
citations

19
h-index

34
g-index

87
ext. papers

1,562
ext. citations

5.6
avg, IF

3.69
L-index

#	Paper	IF	Citations
79	Incidence Rate and Risk Factors for Anal Squamous Cell Carcinoma in a Cohort of People Living With HIV from 2004 to 2017: Implementation of a Screening Program. <i>Diseases of the Colon and Rectum</i> , 2022 , 65, 28-39	3.1	1
78	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. <i>Lancet HIV</i> , 2021 , 8, e531-e543	7.8	14
77	Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. <i>Vaccine</i> , 2019 , 37, 2758-2763	4.1	3
76	High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019 , 7, 62-66	4.6	6
75	High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human Immunodeficiency Virus-infected Men Who Have Sex With Men in Low-to-Absent Cytological Abnormalities. <i>Clinical Infectious Diseases</i> , 2019 , 69, 2185-2192	11.6	7
74	Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. <i>Journal of Medical Virology</i> , 2019 , 91, 1970-1978	19.7	5
73	Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, e1-e5	3.1	2
72	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 699-706	3.4	12
71	Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 247-254	5.3	2
70	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 409.e5-409.e8	9.5	8
69	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017 , 18, 546-554	2.7	4
68	Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. <i>Journal of Infection</i> , 2017 , 74, 514-517	18.9	1
67	HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017 , 18, 126-134		29
66	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 853-861	5.3	4
65	Short-term effect of DAA IFN-free regimens on liver stiffness. <i>Journal of Hepatology</i> , 2017 , 66, S525	13.4	2
64	High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. <i>HIV Medicine</i> , 2017 , 18, 445-451	2.7	8
63	NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b. <i>PLoS ONE</i> , 2017 , 12, e0182193	3.7	4

62	No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014. <i>BMC Infectious Diseases</i> , 2016 , 16, 489	4	5
61	HIV Coinfection Impairs Response to DAA-Based HCV Therapy. <i>Journal of Hepatology</i> , 2016 , 64, S219	13.4	3
60	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 1253-7	2.2	1
59	Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study. <i>PLoS ONE</i> , 2016 , 11, e0155842	3.7	3
58	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. <i>PLoS ONE</i> , 2016 , 11, e0148104	3.7	5
57	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016 , 17, 766-773	2.7	17
56	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1929-36	5.3	6
55	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1879-84	5.3	2
54	Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 2247-55	5.3	5
53	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015 , 71, 571-7	18.9	39
52	Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. <i>Antiviral Therapy</i> , 2015 , 20, 407-13	1.6	
51	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015 , 29, 1927-35	3.5	16
50	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015 , 10, e0125080	3.7	10
49	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1837-48	4	6
48	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014 , 68, 372-7	18.9	3
47	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014 , 9, e95515	3.7	20
46	Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19631	5.4	
45	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014 , 159, 3345-51	2.6	3

44	A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014 , 34, 558-66	7.9	7
43	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014 , 15, 16-24	4.4	15
42	Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4027-9	9.7	22
41	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
40	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013 , 41, 21-6	5.8	6
39	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013 , 85, 1734-40	19.7	8
38	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 1427-35	5.3	9
37	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013 , 67, 59-64	18.9	9
36	Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013 , 31, 424-9	0.9	7
35	Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. <i>Clinical Infectious Diseases</i> , 2013 , 57, 465-8	11.6	76
34	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 915-21	5.1	3
33	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
32	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 905-11	2.2	29
31	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013 , 27, 2715-24	3.5	7
30	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012 , 64, 204-11	18.9	8
29	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012 , 56, 788-94	13.4	33
28	HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. <i>Antiviral Research</i> , 2012 , 95, 212-5	10.8	6
27	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 1225-32	5.3	6

26	Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 202-5	5.1	16
25	Differences in virological response to peginterferon plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 117-23	3.1	12
24	Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfecting patients. <i>HIV Clinical Trials</i> , 2012 , 13, 61-9		16
23	LDLR genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012 , 26, 1009-15	3.5	10
22	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfecting patients with prior nonresponse or relapse. <i>Aids</i> , 2011 , 25, 1131-3	3.5	20
21	Influence of the combination of low-density lipoprotein receptor and interleukin 28B genotypes on lipid plasma levels in HIV/hepatitis C-coinfecting patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, e115-7	3.1	
20	Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfecting patients. <i>HIV Medicine</i> , 2011 , 12, 14-21	2.7	15
19	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011 , 12, 487-93	2.7	15
18	Supplementation of flaxseed oil diminishes skin sensitivity and improves skin barrier function and condition. <i>Skin Pharmacology and Physiology</i> , 2011 , 24, 67-74	3	34
17	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1346-50	5.1	16
16	Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2605-14	5.1	18
15	Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfecting patients receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1629-36	7	55
14	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1351-3	5.1	8
13	Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfecting patients. <i>Aids</i> , 2011 , 25, 1415-20	3.5	36
12	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2204-11	5.1	27
11	Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1209-16	11.6	51
10	Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfecting with HIV and hepatitis C virus. <i>Clinical Infectious Diseases</i> , 2010 , 51, 788-95	11.6	128
9	Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfecting patients using transient elastometry. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 801-7	2.2	23

8	HAART and the liver: friend or foe?. <i>European Journal of Medical Research</i> , 2010 , 15, 93-6	4.8	5
7	Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy. <i>Journal of the International AIDS Society</i> , 2010 , 13, P208-P208	5.4	78
6	Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients. <i>Journal of the International AIDS Society</i> , 2010 , 13, P91-P91	5.4	1
5	Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients. <i>HIV Clinical Trials</i> , 2009 , 10, 276-81		1
4	A review of current anti-HCV treatment regimens and possible future strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 417-33	4	19
3	Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2008 , 654, 8-12	3	26
2	Consumption of flavanol-rich cocoa acutely increases microcirculation in human skin. <i>European Journal of Nutrition</i> , 2007 , 46, 53-6	5.2	80
1	Long-term ingestion of high flavanol cocoa provides photoprotection against UV-induced erythema and improves skin condition in women. <i>Journal of Nutrition</i> , 2006 , 136, 1565-9	4.1	125